검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Second generation CAR-T cells (Second generation CAR-T cells) Wuhan Sian Medical Technology Co.,…·Acute Lymphoblastic Leukemia 46 trials |
|---|---|
Overview Program | Second generation CAR-T cells |
Overview Company | Wuhan Sian Medical Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Second generation CAR-T cells (Second generation CAR-T cells) Wuhan Sian Medical Technology Co.,…·Acute Lymphoblastic Leukemia 46 trials |
|---|---|
Overview Program | Second generation CAR-T cells |
Overview Company | Wuhan Sian Medical Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교